Gentris corporation.
Gentris Corporation is engaged in the development and rapid commercialization of innovative proprietary clinical pharmacogenomic products and services. The company provides global pharmaceutical research organizations with turn-key pharmacogenomic solutions to improve the efficiency and predictability of drug development. The ultimate benefit to these organizations is to shorten drug development cycles, improve new drug approval rates and allow marginal drugs to advance towards final approval. In the near future, the company will develop specialized, high quality, reliable diagnostic products, which will provide physicians and their patients with access to pharmacogenomic testing, as personalized medicine becomes the new standard of medical practice.